SONATA LIFU for OCD

Recruiting Phase 2 Interventional Study
Obsessive Compulsive Disorder
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
22 – 80
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Other
Participants needed
40 (estimated)
Sponsor
University of Pennsylvania · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The study tests ATTN201, an investigational non-invasive headband that delivers low-intensity focused ultrasound (LIFU) to the subthalamic nucleus (STN) as a treatment for obsessive-compulsive disorder (OCD). It's a randomized, double-blind, 1:1 (active: sham) study with 40 total participants spanning 12-16 weeks and 14 in-person and remote visits.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Have a principal diagnosis of OCD according to the DSM-5 with duration of \> 1 year 2. Have a Y-BOCS of \> 16 3. Participants currently on OCD medication must be at the same stable dose(s) for at least 3 weeks prior to screening and throughout the course of the study, and mus…
Contacts

Giovanna Rocchio

6177657150

giovanna.rocchio@pennmedicine.upenn.edu

CONTACT